1341 PharmaBio Delegate Booklet

1341 PharmaBio Delegate Booklet 28/11/07 14:41 Page 4
Monday 3 December 2007
08:00 Registration and Coffee
09:00 CHAIR’S OPENING REMARKS
Mr Andrew Jack, Pharmaceutical Correspondent, Financial Times
New Avenues for Innovation in the Global
Pharmaceutical and Biotechnology Industries
Convergence: Driving Innovation, Accelerating Growth
• How will convergence transform the structure of the global life
sciences and healthcare industries? How is value creation shifting
across all areas of the life sciences and healthcare value chain?
• How can opportunities for innovation through convergence be
optimised?
• Pharma and biotech: converging or diverging futures?
Mr Robert Wessman, President and CEO, Actavis Group
Dr Lisa Drakeman, President and CEO, Genmab
Mr Angus Russell, Chief Financial Officer, Shire plc
Questions and Answers
10:00 Convergence in Practice: Devices, Drugs and IT
• Winners and losers in convergence: how can biotech, device and
diagnostic companies ensure that they are equal partners in the
convergence game?
• Implications for industry structure: to what extent will convergence
lead to the evolution of pharma and biotech companies as broader
‘healthcare companies’?
• Making convergence work: overcoming practical barriers to crosssector
convergence (e.g. managing expectations regarding timelines
for R&D)
Dr Steven Powell, Chief Executive Officer, Plethora Solutions Limited
Mr Simon Hammett, UK Life Sciences and Health Care Practice Leader,
Deloitte
Questions and Answers
10:30 Leveraging Emerging Markets for Innovation and
Revenue Growth
10:45 Coffee
Mr Bob Go, Global Managing Director, Life Sciences and Health Care,
Deloitte
Questions and Answers
11:15 Waking to the Century of Networked Pharma
The Strategic Imperative of Collaboration, Partnerships
and Consolidation
• The implications of the networked pharma model? How is
networking changing the fundamentals of the industry?
• Key to successful partnerships: overcoming organisational and
cultural challenges
Dr Louise Makin, Chief Executive Officer, BTG plc
Mr Dan Zabrowski, Global Head Pharma Partnering, Roche
Questions and Answers
11:45 Public-Private Partnerships
• How can currently fragmented public and private R&D efforts be
brought together more efficiently to create truly life saving innovation?
• What is the opportunity for pharmaceutical and biotechnology
companies in PPPs e.g. creating commercial spin-offs for
pharmaceutical and biotechnology, and providing new funding,
licencing and marketing opportunities for the biotech companies?
• How do PPPs work, and what is the key to their success? How can
the scope and effectiveness be improved?
Dr Jean-Pierre Paccaud, Director of Business Development,
Drugs for Neglected Diseases initiative (DNDi)
Dr Lynn Marks, Senior Vice President, Infectious Diseases Medicine
Development Centre, GlaxoSmithKline
Questions and Answers
–– 4 ––
12:15 Panel: Delivering Innovation through Effective Licensing
– Next Frontiers
• Examining the opportunities and pitfalls of licensing in Asia and
emerging markets: does licensing in emerging markets hold the key
to success of stand-alone biotech?
• Strategies for growth: licensing vs. M&A
• Emerging licensing structures and deal terms-what are the
emerging innovations?
Dr Geoffrey Guy, Executive Chairman, GW Pharmaceuticals Plc
Dr Simon Moroney, Chief Executive Officer, MorphoSys AG
Mr John Mayo CBE, Managing General Partner, Celtic Pharma
12:45 Panel: Mergers and Acquisitions – Reshaping the
Pharma Future?
• How will the current round of M&A transform the landscape of the
industry?
• What are the broader implications of pharma’s current appetite for
biotech acquisitions for innovation in the industry?
• What are the particular challenges relating to integrating biotech
acquisitions for pharmaceutical companies? e.g. keeping the culture
of innovation alive?
• Assessing the implications of the rise of acquisitive emerging market
pharma companies as international players
Mr Shinichi Tamura, President and CEO, Sosei Group Corporation
Mr John Goddard, Senior Vice President, Strategic Planning and
Business Development, AstraZeneca plc
Ms Kate Bingham, Managing Partner, SV Life Sciences
13:15 Networking Lunch
14:30 CHAIR
Mr Martyn Postle, Director and Founder,
Cambridge Healthcare and Biotech Ltd
Leveraging Customer Collaboration
14:40 New Approaches to Collaboration with Government
Mr Meindert Boysen, Associate Director – Single Technology
Appraisals, National Institute of Clinical Excellence (NICE)
15:00 Patients: Riding the Rising Tide of Healthcare
Consumerism
15:30 Coffee
Mr Simon Denegri, Chief Executive,
Association of Medical Research Charities (AMRC)
Questions and Answers
16:00 Innovation and the Global Pharmaceutical,
Biotech and Medical Devices Industries
Exploring the Vital Link Between Pricing and Innovation:
New Business Pricing Models and Reimbursement
Dr Panos Kanavos, Lecturer, International Health Policy,
London School of Economics
Ms Ann Pope, Director, Markets and Projects-Goods,
Office of Fair Trading (OFT)
Questions and Answers
16:30 Funding for Innovation
Dr Andy Richards, Early Stage Biotechnology Investor
Mr Ted Bianco, Director of Technology Transfer, Wellcome Trust
Questions and Answers
17:00 Networking Drinks Reception
The organisers reserve the right to alter the programme and speakers as may be necessary.
© Financial Times Limited 2007.